2018. Patient Preference for Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam or Topical Suspension vs. Latest Topical Treatment in the PSO-INSIGHTFUL Study. SKIN The Journal of Cutaneous Medicine. 2, S1 (Feb. 2018), S10. DOI:https://doi.org/10.25251/skin.2.supp.10.